ATRA Q1 2025 Earnings Report on 5/15/2025
As of 05/14/2025 04:00 PM Eastern
- Actual Revenue
- Expected Revenue
- Beat/Miss
- YoY Revenue Growth
- Quarter
- Date
- Time
- Conference Call Date
- Conference Call Time
Get Earnings Announcements in your inbox
Want to stay updated on the latest earnings announcements and upcoming reports for companies like Atara Biotherapeutics? Sign up for to receive timely earnings updates on Atara Biotherapeutics and other key companies, straight to your email.
Atara Biotherapeutics (NASDAQ:ATRA) engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA3219, currently in Phase 1 trials, as well as ATA3431, under preclinical trials for the treatment of B-cell malignancies and autoimmune diseases; and ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.
Earnings Tools
Latest Articles
Get 30 Days of MarketBeat All Access for Free
Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools.
